Overall, the researchers concluded that the beta-glucan supplement consistently stimulated immune cells throughout the study which suggests that daily intake augments acquired immunity.
Photo © AdobeStock.com/marina_ua
A recent pilot study1 found that supplementation with a branded beta-glucan, called PureMune from Immudyne Nutritional (Jacksonville, FL), helped reduce the risk of upper respiratory tract infection. In the study, 12 healthy subjects receive 30 mg of beta-glucan daily for 90 days during flu season. Subjects were examined at baseline, 30 days, 60 days, and 90 days.
Results showed that supplementation with the beta-glucan reduced the number of symptomatic upper respiratory infections by 44%, compared the same time period the previous year. For those that did get sick, supplementation reduced the duration of upper respiratory tract infections by 50%, compared to the previous year. Researchers also found that serum levels of IFN-γ, IL-2 and IFN-γ/IL-4 ratio increased significantly compared to baseline. Serum levels of IFN-γ were significantly higher at day 30, day 60 and day 90 while IL-2 levels were significantly higher at day 30 and day 60. The ratio of IFN-γ/IL-4 saw was significantly higher at day 30, day 60, and day 90.
Overall, the researchers concluded that the beta-glucan supplement consistently stimulated immune cells throughout the study which suggests that daily intake augments acquired immunity.
Reference
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.